PDS Biotechnology
PDSB
80 hedge funds and large institutions have $39.9M invested in PDS Biotechnology in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 21 increasing their positions, 18 reducing their positions, and 18 closing their positions.
72% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 18
18% more funds holding
Funds holding: 68 → 80 (+12)
17% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 18
8% more call options, than puts
Call options by funds: $1.47M | Put options by funds: $1.36M
0.81% more ownership
Funds ownership: 24.93% → 25.74% (+0.81%)
20% less capital invested
Capital invested by funds: $49.8M → $39.9M (-$9.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.34M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.32M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.14M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.87M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.67M |
| 2 |
EWA
EP Wealth Advisors
Torrance,
California
|
-$2.91M |
| 3 |
Two Sigma Investments
New York
|
-$2.32M |
| 4 |
Renaissance Technologies
New York
|
-$2.25M |
| 5 |
First Manhattan
New York
|
-$1.67M |
PDSB Hedge Fund Activity: Q2 2023 in Review
80 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q2 2023, worth a combined $39.9M — down 20% from $49.8M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new PDSB positions and 18 closed out — a net gain of 13 holders — while 21 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $8.34M. The largest seller was Millennium Management, exiting entirely with an estimated $3.67M sold.
- 80 institutional investors held PDS Biotechnology (PDSB) as of Q2 2023, up from 68 in Q1 2023.
- Funds reported $39.9M of PDS Biotechnology stock for Q2 2023, down 20% quarter-over-quarter.
- 31 funds opened new PDS Biotechnology positions in Q2 2023 and 18 closed out, a net change of +13 holders.
- The largest PDS Biotechnology buyer in Q2 2023 was BlackRock, an estimated $8.34M added.
- The largest PDS Biotechnology seller in Q2 2023 was Millennium Management, an estimated $3.67M sold.
Based on aggregated 13F filings for Q2 2023.